Abstract:Identification of immunogenic targets against hepatitis B virus (HBV)-encoded proteins will provide crucial advances in developing potential antibody therapies. In this study, 63 treatment-naive patients with chronic HBV infection and 46 patients who achieved hepatitis B surface antigen loss (sAg loss) following antiviral treatment were recruited. Moreover, six patients who transitioned from the hepatitis B e antigen-positive chronic infection phase (eAg(+)CInf) to the hepatitis phase (eAg(+)CHep) were enrolled from real-life clinical practice. Additionally, telbivudine-treated eAg(+)CHep patients and relapsers or responders from an off-treatment cohort were longitudinally studied. The frequencies and function of B cells were assessed by flow cytometry. We devised a peptide array composed of 15-mer overlapping peptides of HBV-encoded surface (S), core (C), and polymerase (P) proteins and performed a screening on B-cell linear epitopes with sera. Naive B cells and plasmablasts were increased, whereas total memory, activated memory (AM), and atypical memory (AtM) B cells were reduced in sAg(-) patients compared with sAg(+) patients. Importantly, longitudinal observations found that AtM B cells were associated with successful treatment withdrawal. Interestingly, we identified six S-specific dominant epitopes (S33, S34, S45, S76, S78, and S89) and one C-specific dominant epitope (C37) that reacted with the majority of sera from sAg(-) patients. Of note, more B-cell linear epitopes were detected in CHep patients with alanine aminotransferase (ALT) flares than in nonflare CInf patients, and five B-cell linear epitopes (S4, S5, S10, S11, and S68) were overwhelmingly recognized by ALT flare patients. The recognition rates of epitopes on C and P proteins were significantly increased in CHep patients relative to CInf patients. Strikingly, a statistically significant elevation in the number of positive epitopes was observed when ALT nonflare patients shifted into the flare phase. Moreover, S76 identified at baseline was confirmed to be associated with a complete response after 48 weeks of telbivudine therapy. Taken together, we identified several functional cure-related B-cell linear epitopes of chronic HBV infection, and these epitopes may serve as vaccine candidates to elicit neutralizing antibodies to treat HBV infection.

A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy

Identification and Mapping of HBsAg Loss-Related B-Cell Linear Epitopes in Chronic HBV Patients by Peptide Array

A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations

Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen

TCR-like bispecific antibodies toward eliminating infected hepatocytes in HBV mouse models

A Bispecific Antibody Against Two Different Epitopes on Hepatitis B Surface Antigen Has Potent Hepatitis B Virus Neutralizing Activity.

A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice

Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B

HBsAg and TLR7/8 dual-targeting antibody-drug conjugates induce sustained anti-HBV activity in AAV/HBV mice: a preliminary study

A Single Dose of Anti-HBsAg Antibody-Encoding Mrna-Lnps Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection

Novel monkey mAbs induced by a therapeutic vaccine targeting the hepatitis B surface antigen effectively suppress hepatitis B virus in mice

Prokaryotic Expression of a Novel Therapeutic recombinant transbody H2L2 Targeting Hepatitis B Virus core protein

A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression

A Human Monoclonal Antibody Against Small Envelope Protein of Hepatitis B Virus with Potent Neutralization Effect.

Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein

Lymph node-targeted STING agonist nanovaccine against chronic HBV infection

Hepatitis B surface antigen and functional cure of chronic hepatitis B

Vaccines Targeting PreS1 Domain Overcome Immune Tolerance in HBV Carrier Mice

Neutralization Effects of Antibody Elicited by Chimeric HBV S Antigen Viral-Like Particles Presenting HCV Neutralization Epitopes.

A human-derived protein SBP (HBsAg-binding protein) can bind to hepatitis B virus surface antigen (HBsAg) and enhance the immune response to hepatitis B virus (HBV) vaccine.

Lentiviral Vector Encoding Ubiquitinated Hepatitis B Core Antigen Induces Potent Cellular Immune Responses and Therapeutic Immunity in HBV Transgenic Mice